Vernalis Share Discussion Threads

[cockneytrader] 01/5/2015 07:33

These should fly!

[fhmktg] 30/4/2015 17:27

And that's before the PDUFA!
Once this is in the bag- the rest of the portfolio should follow without incident and we will have a new cash stream for when Frova patents expire- that's what MR W is counting on IMHO
For fellow British Biotech holders- keep the faith!

[twodegrees] 30/4/2015 16:12

gone from 16% to 19% holding in a week...I am glad after 10 years re old british biotech shares that I have held on

[twodegrees] 30/4/2015 16:11

And still he increases his holding...now 19%...he knows something that we do not.

I note however not many trades by p.i's...is the message not getting heard

[fhmktg] 30/4/2015 11:14

Tuzista PDUFA today- fingers crossed!

[cockneytrader] 23/4/2015 18:47

No brainer.

[fhmktg] 23/4/2015 17:39

Sorry- PDUFA!

[fhmktg] 23/4/2015 17:38

The PDFs for Tuzistra is scheduled for April 30th.Given approval, Vernalis should begin selling in time for the next cough/cold season.Should bode well for a steady approval process for the following products!

[toffeeman4] 23/4/2015 15:56

Hope not tempting fate, but feel the news due shortly is going to be good,as I'm sure Neil Woodford does !

[fhmktg] 23/4/2015 15:00

Mr Woodford no less!
Now at 17.5%
Come on market,wake up for goodness sakes!

[fhmktg] 10/4/2015 15:42

That's some steady buying!

[fhmktg] 06/3/2015 09:18

Mr Woodford will be pleased!

[zubairlk] 06/3/2015 07:20

6 March 2015LSE: VERVernalis and Asahi Kasei Pharma Achieve Research MilestoneVernalis is pleased to announce the achievement of the second milestone in its drug discovery collaboration with Asahi Kasei Pharma (AKP). Vernalis will receive a payment of GBP0.5m in recognition of this achievement.This collaboration with AKP was initiated in October 2013 and utilises Vernalis' fragment and structure-based drug discovery platform against an undisclosed target for rheumatoid arthritis and other autoimmune diseases. Overall financial terms of this collaboration have not been disclosed.-- ends --Cool

[zubairlk] 03/3/2015 16:57

800k shares bought at 48p at 9:46 today..Someone still buying a ton..

[fhmktg] 26/2/2015 09:25

This is a good one to get away for licensing- the proof of concept trials must have enough promise to convince the investors to take the risk with phase II/III work where the real costs are. ADHD MIGHT not be the key area of interest for the US partner= MS or Parkinsons will come into consideration.
hHe next development area V158866 for neuropathic pain would be a potential biggy- data due this year.

[zubairlk] 26/2/2015 07:17

Cool RNSVernalis plc today announces that it has licensed exclusive, worldwide rights in its adenosine receptor antagonist programme, including the lead drug candidate, V81444, for use in all therapeutic applications to a well-funded, US-based biotechnology company. The transaction includes a $1 million upfront payment and has the potential for Vernalis to earn over $200 million subject to development, regulatory and sales milestones being achieved. In addition there are single digit royalties payable if a product reaches the market, with the potential to reach double digit royalties in certain circumstances.The licensing party is a private US company, that has raised a large Series A round with leading venture capital investors, and brings a management team with a wealth of clinical and commercial expertise and experience to this programme.V81444 is a patented molecule that has been evaluated in phase I and II clinical trials under an IND in the US. Its initial development was focused on ADHD and other neurological diseases.Commenting on the new relationship, Ian Garland, CEO of Vernalis said "We are delighted to have secured an ideal partner for V81444 and our adenosine receptor antagonist programme and look forward to the development of V81444 and this interesting class of compounds for the potential benefit of patients worldwide."

[zubairlk] 25/2/2015 17:31

The volumes of this share are surprising. Nothing happens.N then a bucket load are bought/sold..Looks like someone is off loading. But the share price didn't budge much.Yesterday it went down on very low volume and I bought some in hopes of an easy rebound.

[fhmktg] 24/2/2015 13:41

Perhaps he reads his briefing papers on Vernalis and recognises the potential once the cough meds start to come through...his capital fund has 'Patience'in its title= perhaps that's the key!

Keep the faith!

[zubairlk] 24/2/2015 11:21

Why is the price falling on such low volume? And it didn't go up when woodford bought millions?

[fhmktg] 18/2/2015 13:04

Mr W STILL buying, now over 15%
Come on market R$ESPOND; this is one of the canniest investors buying in.

[fhmktg] 12/2/2015 19:15

...and another 1.9 million- who is buying and who is releasing?
STILL no boost to the SP!

[fhmktg] 11/2/2015 13:50

The Hoovering up of shares continues- 3 million bought and counting!

[fhmktg] 10/2/2015 23:54

Market cap of around £250 million would be a tasty morsel for btg. Not sure about the synergies though.

[battyliveson] 10/2/2015 16:47

I would have thought that this business would be a good acquisition for BTG. Chair of BTG has worked with Vernalis CEO in past and knows he is good and would be a good addition to the enlarged business. The cold cures seems to fit with BTG portfolio.

I guess I should just be patient like Woodford and wait for it to come good.

[fhmktg] 10/2/2015 16:34

3.5 million bought and no push on the sp- strange!